Summary
Regeneron Pharmaceuticals, Inc. (REGN) announced in an 8-K filing on January 2, 2018, that Robert J. Terifay, Executive Vice President of Commercial, has resigned from his position, effective January 5, 2018. Mr. Terifay has requested a personal medical leave of absence until July 31, 2018, during which he will retain access to company health insurance plans but will not receive any cash compensation. Following his leave of absence, Mr. Terifay will retire on July 31, 2018. Post-retirement, he will continue to have his health insurance plans subsidized by Regeneron through January 31, 2020. The company is actively searching for a successor for Mr. Terifay's role. This executive departure is the primary focus of this filing.
Key Highlights
- 1Robert J. Terifay resigns as EVP, Commercial, effective January 5, 2018.
- 2Mr. Terifay is taking a personal medical leave of absence until July 31, 2018.
- 3During the leave, Mr. Terifay will not receive cash compensation but will maintain health insurance benefits.
- 4Mr. Terifay will retire upon the conclusion of his leave of absence on July 31, 2018.
- 5Regeneron will subsidize Mr. Terifay's health insurance through January 31, 2020, post-retirement.
- 6The company is initiating a search for a replacement for the EVP, Commercial position.